Department of Surgical Oncology, Fortis Hospital, Bangalore, India.
Department of Pathology, Fortis Hospital, Bangalore, India.
Eur J Surg Oncol. 2018 Jul;44(7):1105-1111. doi: 10.1016/j.ejso.2018.03.032. Epub 2018 Apr 12.
The pathological classification of PMP of appendiceal origin has prognostic and treatment implications. Our goals were to • Classify low grade mucinous carcinoma peritonei (LGMCP) into prognostically distinct subgroups based on histological features. • Compare the reproducibility of the WHO and the PSOGI classifications for both PMP and the appendiceal primary tumor.
A retrospective analysis of patients undergoing CRS and HIPEC or debulking surgery was done. All the tumors were re-classified according to the PSOGI classification. LGMCP was further classified into three histological subgroups and the impact on survival was evaluated.
From Jun 2011 to June 2016, 101 patients underwent CRS with HIPEC (n = 89) or debulking surgery (n=12). The median PCI was 28 (3-39) and 74.1% patients had CC-0/1 resections. Of the 76.2% patients who had LGMCP, 4 patients (5.1%) were classified as group 1, 54 (70.1%) as group 2 and 19 patients (24.6%) as group 3. At a median follow up of 21 months, the disease free survival was not reached, 30 months and 14 months for groups 1, 2 and 3 respectively (p = 0.09). There was no difference in overall survival. Using the WHO classification, there was a discordance in the grade of the primary tumor and the peritoneal lesions in 19.8% and conflicting terminology was used in 62% of patients.
The subgroups of LGMCP described here are prognostically different though this needs further prospective evaluation in larger series. The PSOGI classification is more uniformly reproducible and should be preferred to the WHO classification.
阑尾来源的 PMP 的病理分类具有预后和治疗意义。我们的目标是:
根据组织学特征将低级别黏液性腹膜癌(LGMCP)分为预后不同的亚组。
比较 WHO 和 PSOGI 分类对 PMP 和阑尾原发性肿瘤的可重复性。
对接受 CRS 和 HIPEC 或减瘤手术的患者进行了回顾性分析。所有肿瘤均根据 PSOGI 分类重新分类。进一步将 LGMCP 分为三个组织学亚组,并评估其对生存的影响。
2011 年 6 月至 2016 年 6 月,101 例患者接受了 CRS 联合 HIPEC(n=89)或减瘤手术(n=12)。中位 PCI 为 28(3-39),74.1%的患者行 CC-0/1 切除。在 76.2%的 LGMCP 患者中,4 例(5.1%)患者为 1 组,54 例(70.1%)为 2 组,19 例(24.6%)为 3 组。中位随访 21 个月时,1 组、2 组和 3 组的无疾病生存率分别为未达到、30 个月和 14 个月(p=0.09)。总生存率无差异。使用 WHO 分类,原发性肿瘤和腹膜病变的分级存在差异的比例为 19.8%,使用的术语不一致的比例为 62%。
这里描述的 LGMCP 亚组具有不同的预后,但这需要在更大的系列中进一步前瞻性评估。PSOGI 分类更具一致性,应优先于 WHO 分类。